BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» GSK, ImmunoGen Ending Deal To Develop TAP Cancer Drug
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
GSK, ImmunoGen Ending Deal To Develop TAP Cancer Drug
Jan. 27, 2003
By
Randy Osborne
No Comments
Unable to find a retooled deal pleasing to both sides, ImmunoGen Inc. and GlaxoSmithKline plc - which earlier said they were striving to do so - have ended their development agreement for cantuzumab mertansine (huC242-DM1). (BioWorld Today)
BioWorld